🎉 Congratulations to today's "Daily Best" winners!
Each receives 50 USDT for their outstanding in-depth articles! 👏
📝 Today's winners & articles
@Mr_qiang777 https://www.gate.com/post/status/19028534
@Coinstages https://www.gate.com/zh/post/status/19031206
@PlayerYU https://www.gate.com/zh/post/status/19038966
🔥 The event is heating up — 3 winners are selected daily!
You could be tomorrow's pick! Share your market insights now and win 50 USDT plus official exposure!
👉 Join now: gate.com/post
#GateSquare #DeepCreationCamp #DailyBest
PFIZER INC SEC 10-K Report
Pfizer Inc. has released its 2025 Form 10-K report, detailing a 2% decrease in total revenues to $62.6 billion, primarily due to operational declines, with reported diluted EPS at $1.36 and adjusted diluted EPS up by 4% to $3.22. The report highlights strategic initiatives focused on R&D, market leadership, and cost realignment, while addressing significant challenges including pricing pressures, competition, patent expirations, and geopolitical risks. Pfizer aims to maximize key transactions, achieve R&D milestones, and invest in post-2028 growth, along with committing to net-zero emissions by 2040.